Sustained Or Differential Release Type Patents (Class 514/964)
-
Patent number: 6518313Abstract: Solid sanitizing compositions have advantages over corresponding liquids and powders. A solid sanitizing product can be contained within a plastic bottle with a label indicating that the contents have antimicrobial or deodorizing properties containing a non-flowable solid composition having greater than about 0.02 percent by weight antimicrobial compounds. The preferred solid sanitizing compositions consist essentially of an antimicrobial compound selected from the group consisting of quaternary ammonium salts, fatty amines and diamines, chlorhexidine gluconate, phenol, derivatives of phenol, parachloro metaxylenol and mixtures thereof, and between 0 and 99.98 percent by weight of a cleaning composition. The solid sanitizing compositions can be effectively used with solid dispensers. The solid dispensers have a bowl with a drain at the bottom and an upward pointing spray nozzle.Type: GrantFiled: February 8, 2001Date of Patent: February 11, 2003Assignee: Sunburst Chemicals, Inc.Inventor: William H. Scepanski
-
Patent number: 6517868Abstract: Disclosed herein is a tableted oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.Type: GrantFiled: November 30, 2001Date of Patent: February 11, 2003Inventors: A. Reza Fassihi, Thomas Dürig
-
Patent number: 6503883Abstract: The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the production of the pharmaceutical preparation.Type: GrantFiled: November 28, 2000Date of Patent: January 7, 2003Assignee: Novartis AGInventor: Ulrich Posanski
-
Patent number: 6491953Abstract: A controlled release composition comprising an adsorbent polymer, an active agent, and a release retardant is disclosed. The composition has an improved ability to release the active agent over an extended time period.Type: GrantFiled: January 7, 2000Date of Patent: December 10, 2002Assignee: Amcol International CorporationInventors: Milan F. Sojka, Ralph Spindler
-
Patent number: 6488965Abstract: Antimicrobial/pharmaceutical preparations (e.g., solutions, gels, ointments, creams, sustained release preparations, etc.) which comprise chlorite (e.g., a metal salt of a chlorite) in combination with a peroxy compound (e.g., hydrogen peroxide), and methods for using such preparations for disinfection of articles or surfaces (e.g., contact lenses, counter tops, etc.), antisepsis of skin or other body parts, prevention or deterrence of scar formation and/or treatment and prophylaxis of dermal (i.e., skin or mucous membrane) disorders (e.g., wounds, burns, infections, cold sores, ulcerations, psoriasis, acne, or other scar-forming lesions).Type: GrantFiled: November 27, 2000Date of Patent: December 3, 2002Inventor: Hampar L. Karageozian
-
Patent number: 6482864Abstract: A method for producing a sustained-release preparation, which comprises dispersing a physiologically active polypeptide into an organic solvent solution of a biodegradable polymer and removing the organic solvent, wherein the polypeptide is a powder obtained by lyophilizing an aqueous solution of the polypeptide which solution has a water-miscible organic solvent and/or a volatile salt; which improves the ease of handling of the physiologically active polypeptide powder in the process for producing the preparation; which makes it possible to industrially produce the sustained-release preparation in large scale; which provides a sustained-release preparation showing high and stable concentration of the active component in blood in long term, low initial release ratio of the physiologically active polypeptide, and high entrapment ratio of the polypeptide into the sustained-release preparation.Type: GrantFiled: May 28, 1999Date of Patent: November 19, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yutaka Yamagata, Masafumi Misaki, Susumu Iwasa
-
Patent number: 6479551Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.Type: GrantFiled: March 3, 2000Date of Patent: November 12, 2002Assignee: Pozen Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan
-
Patent number: 6479065Abstract: The invention relates to a sustained release composition and methods of forming and using said composition for the sustained release of biologically active agent. The sustained release compositions of the invention comprise a biocompatible polymer and a biologically active agent characterized by a porous center and a less porous outer layer wherein the center and outer layer consist of essentially the same materials. The sustained release compositions can be prepared by annealing at least a substantial portion of the exterior surface of a polymer/active agent matrix. The compositions which have been annealed exhibit a decrease in the release of agent over the first 24 hours following administration (i.e., reduced burst) and as a result can show an increase in the duration of sustained release thereby providing increased therapeutic benefits.Type: GrantFiled: March 7, 2001Date of Patent: November 12, 2002Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Warren E. Jaworowicz, James I. Wright
-
Patent number: 6458763Abstract: The present invention is directed to bioactive compositions that induce the repair of damaged or diseased connective tissues upon contact of the damaged or diseased tissues with the composition in vivo. More particularly the present invention is directed to the use of compositions comprising an effective amount of bone sialoprotein to enhance the repair of damaged or diseased bone.Type: GrantFiled: September 17, 1999Date of Patent: October 1, 2002Assignee: DePuy OrthopeadicsInventors: Dale R. Peterson, Nancy Nousek-Goebl, Todd P. Glancy
-
Patent number: 6451348Abstract: A method of manufacturing a porous matrix-type drug delivery system is provided. It comprises the steps of: dispersing, stirring, and emulsifying an aqueous solution of a drug in an organic solvent having a polymer compound and a surface active agent solved therein; thereafter forming it into a desirable matrix shape; lyophilizing or drying it at a low temperature or room temperature until the matrix surface is hardened; and drying it again in order to remove the water and the organic solvent.Type: GrantFiled: January 3, 2000Date of Patent: September 17, 2002Assignee: Korea Institute of Science and TechnologyInventors: Seo Young Jeong, Kuiwon Choi, Ick-Chan Kwon, Yong-Hee Kim, Jae Bong Choi, Kyu Back Lee
-
Patent number: 6451351Abstract: A method for preparing a gel composition, such as alginate gel beads, using a proper concentration of calcium pantothenate or calcium ascorbate as a gelling agent.Type: GrantFiled: July 3, 2000Date of Patent: September 17, 2002Assignees: Meiji Milk Products Co., Ltd.Inventors: Susumu Kawashima, Yoshifumi Murata
-
Patent number: 6440457Abstract: The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.Type: GrantFiled: May 27, 1993Date of Patent: August 27, 2002Assignee: Alza CorporationInventors: David Emil Edgren, Gurdish Kaur Bhatti, Zahedeh Hatamkhani, Patrick S. L. Wong
-
Patent number: 6437000Abstract: The present invention is directed to a pharmaceutical composition, preferably in the form of a tablet comprising a therapeutically effective amount of a medicament in a carrier comprising a water insoluble polymer and a water-insoluble inorganic salt.Type: GrantFiled: August 30, 2000Date of Patent: August 20, 2002Assignee: Norstrum Pharmaceuticals, Inc.Inventor: Nirmal Mulye
-
Patent number: 6436444Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The .compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.Type: GrantFiled: September 26, 1997Date of Patent: August 20, 2002Assignee: Ecolab Inc.Inventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
-
Publication number: 20020103086Abstract: Controlled release formulations for pesticides and herbicides contain an active ingredient, a matrix polymer and a matrix polymer plasticizer which is present in an amount sufficient to provide a release rate for the active ingredient from the formulation that matches a selected release rate. Methods for making and using the formulation, and seeds and plants that have been treated with the formulations are also included.Type: ApplicationFiled: September 10, 2001Publication date: August 1, 2002Inventors: Jawed Asrar, James F. Essinger
-
Patent number: 6423340Abstract: Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as relapse preventing therapy for Crohn's colitis in its chronic phase and Crohn's disease in the small intestine.Type: GrantFiled: September 23, 1998Date of Patent: July 23, 2002Assignee: Aktiebolaget DracoInventor: Jan Ulmius
-
Patent number: 6420436Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.Type: GrantFiled: June 19, 1998Date of Patent: July 16, 2002Assignee: Alliance Pharmaceutical Corp.Inventor: W. Dean Kirkland
-
Patent number: 6416790Abstract: The concentrate is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 microhmo to about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The liquid concentrate is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.Type: GrantFiled: March 13, 2000Date of Patent: July 9, 2002Assignee: Aqua Med, Inc.Inventor: John D. Young
-
Patent number: 6395765Abstract: Composition which is useful in particular for the treatment and protection of domestic animals which are infested with parasites or are likely to be infested with them, these compositions comprising, in the form of a ready-to-use solution: a) an insecticidal active substance of formula (I), b) a crystallization inhibitor, c) an organic solvent having a dielectric constant of between 10 and 35, preferably of between 20 and 30, d) an organic co-solvent having a boiling point below 100° C., preferably below 80° C., and a dielectric constant of between 10 and 40, preferably of between 20 and 30.Type: GrantFiled: September 25, 1996Date of Patent: May 28, 2002Assignee: MerialInventor: Jean Pierre Etchegaray
-
Patent number: 6391341Abstract: The present invention relates to multi-unitary pharmaceutical preparations containing piroxicam for oral administration. Such pharmaceutical preparations are stable pellet pharmaceutical preparations containing piroxicam and they comprise an amount of active ingredient of between 5 and 50 mg, an inert core with spherical symmetry and a diameter of 600-850 &mgr;m, constituted by inert excipients, coated with an active layer containing piroxicam in micronized form and various pharmaceutically acceptable inert excipients, mixed in appropriate proportions in order to allow the adequate disaggregation of the formulations and dissolution of the active ingredient, coated in it turn with an insulating layer of a polymeric nature and soluble in water, this layer being coated finally with a gastroresistant or enteric layer of a minimum thickness of 20 &mgr;m. This invention also refers to the process for the preparation of said pharmaceutical preparations.Type: GrantFiled: May 30, 2000Date of Patent: May 21, 2002Inventors: Carla Patricia Goncalves Mendes, Maria Julia Caeiro Ramalho de Oliveira
-
Patent number: 6383509Abstract: A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.Type: GrantFiled: August 7, 2001Date of Patent: May 7, 2002Assignee: Allergan Sales, Inc.Inventors: Stephen Donovan, Daniel G. Brady
-
Publication number: 20020042345Abstract: The present invention describes the combination of an agrochemically active compound with a polymer with formation of hydrogen bonds for the controlled release of this active compound. Both the polymer and active compound have functional groups which permit the formation of hydrogen bonds.Type: ApplicationFiled: May 10, 2001Publication date: April 11, 2002Inventors: Jean Kocur, Gerhard Frisch, Jochen Wurtz, Udo Bickers, Erwin Hacker, Hans Philipp Huff, Gerhard Schnabel
-
Patent number: 6369062Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.Type: GrantFiled: March 29, 2000Date of Patent: April 9, 2002Assignees: CV Therapeutics, Inc., Syntex (USA) Inc.Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
-
Patent number: 6368632Abstract: Method of treating warm blooded animals suffering from psychotic disorders. The method includes administering a pharmaceutically effective amount of sustained-release microparticles that include risperidone, or a pharmaceutically acceptable acid addition salt thereof, and a biodegradable and biocompatible polymeric matrix.Type: GrantFiled: May 26, 2000Date of Patent: April 9, 2002Assignees: Janssen Pharmaceutica, Alkermes Controlled Therapeutics Inc. IIInventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
-
Publication number: 20020037309Abstract: The invention relates to a sustained release composition and methods of forming and using said composition for the sustained release of biologically active agent. The sustained release compositions of the invention comprise a biocompatible polymer and a biologically active agent characterized by a porous center and a less porous outer layer wherein the center and outer layer consist of essentially the same materials. The sustained release compositions can be prepared by annealing at least a substantial portion of the exterior surface of a polymer/active agent matrix. The compositions which have been annealed exhibit a decrease in the release of agent over the first 24 hours following administration (i.e., reduced burst) and as a result can show an increase in the duration of sustained release thereby providing increased therapeutic benefits.Type: ApplicationFiled: March 7, 2001Publication date: March 28, 2002Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: Warren E. Jaworowicz, James I. Wright
-
Publication number: 20020026005Abstract: A bioadhesive composition for use as a skin adhesive, the composition formed by polymerising with cross-linking and/or entanglement an aqueous reaction mixture comprising effective amounts of at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water, said composition having an elastic modulus (G′) and a viscous modulus (G″), wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of tan delta (G″÷G″) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s, typically the lower end of the said frequency range below about 100 rad/s.Type: ApplicationFiled: July 27, 2001Publication date: February 28, 2002Inventor: Hugh Semple Munro
-
Patent number: 6340671Abstract: The invention relates to certain stable microsphere compositions containing a fat, a wax or a mixture thereof; an active ingredient selected from LL-F28249&agr;-&lgr; compounds, 23-oxo or 23-imino derivatives of LL-F28249&agr;-&lgr; compounds, milbemycin compounds and avermectin compounds; an antioxidant and, optionally, an oil, a semi-soft fat, a fatty acid derivative or mixture thereof. The invention also relates to a method for introducing and maintaining levels of the active compound in the blood of warm-blooded animals for extended periods of time and for the prevention or treatment of infections and infestations caused by helminths, nematodes, acarids and endo- and ectoparasitic arthropods in warm-blooded animals by the parenteral administration of compositions of the invention.Type: GrantFiled: June 22, 1994Date of Patent: January 22, 2002Assignee: American Cyanamid CompanyInventors: Susan Mancini Cady, William David Steber, Phillip Wayne Hayes, Mary Ehlers Doscher, Kurt Allen Schwinghammer
-
Patent number: 6306423Abstract: A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.Type: GrantFiled: June 2, 2000Date of Patent: October 23, 2001Assignee: Allergan Sales, Inc.Inventors: Stephen Donovan, Daniel G. Brady
-
Patent number: 6306425Abstract: An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances.Type: GrantFiled: April 7, 2000Date of Patent: October 23, 2001Assignee: Southern Research InstituteInventors: Thomas R. Tice, Jay K. Staas, Teresa M. Ferrell
-
Patent number: 6303144Abstract: A controlled release preparation containing at least one kind of a pharmaceutically active ingredient, a male piece and a female piece, the pieces fitting together to enclose the active substance therein, wherein the male piece is made from a material that gels in the intestinal juice, is disclosed. In a preferable mode, the male piece contains an ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer and a methacrylic acid-ethyl acrylate copolymer. In a preferable mode, the female piece is made from a water insoluble polymer. In a preferable mode, the dosage form is a tablet or a capsule.Type: GrantFiled: August 10, 2000Date of Patent: October 16, 2001Assignee: Welfide CorporationInventor: Tomoyuki Omura
-
Patent number: 6271174Abstract: Improved cation exchange zeolite crystalline and zeolite-like plant bed structures are disclosed, preferably saturated with water-based extracts of particular plant/herb materials exhibiting plant growth acceleration properties and synergistically providing also nutrient, and sometimes anti-microbial and insect and fungus repellent properties, as well, and with the adaptability to present the structures in solid, gel and liquid form.Type: GrantFiled: July 28, 1997Date of Patent: August 7, 2001Assignee: Allor FoundationInventors: Robert H. Rines, Lisa Toth, Suzi Rines Toth
-
Patent number: 6262127Abstract: This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF&agr;, e.g., certain autoimmune and inflammatory conditions, as well as septic shock.Type: GrantFiled: July 20, 1999Date of Patent: July 17, 2001Assignee: Novartis AGInventors: Murat Acemoglu, Siegfried Bantle, David Bodmer, Salvatore Cammisuli, Peter Hiestand, Fritz Nimmerfall, Georg Stoll
-
Publication number: 20010007679Abstract: A method and composition are disclosed utilizing the pure (S,R) isomer of formoterol, which is a bronchodilator with reduced adverse effects. (S,R)-Formoterol may be conveniently and safely formulated for aerosol administration.Type: ApplicationFiled: May 10, 1999Publication date: July 12, 2001Inventors: THOMAS P. JERUSSI, CHRIS HUGH SENANAYAKE
-
Patent number: 6258830Abstract: The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.Type: GrantFiled: March 1, 1999Date of Patent: July 10, 2001Assignee: Allergan Sales, Inc.Inventor: Prakash M. Charu
-
Patent number: 6251430Abstract: Sustained release drug formulations contain the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) water insoluble polymer, such as ethyl cellulose, (2) pH dependent gelling polymer, such as sodium alginate, and (3) a pH independent gelling polymer, such as hydroxypropyl methylcellulose. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.Type: GrantFiled: February 4, 1998Date of Patent: June 26, 2001Inventors: Guohua Zhang, Prasad Pinnamaraju, Muhammad A. Ali
-
Patent number: 6245360Abstract: A single entity product is provided for administration to persons being treated for nutritional deficiencies associated with addiction to alcohol, wherein the product is an extended-release multivitamin with minerals and trace elements in beneficial dose ranges and specifically contains thiamine and folic acid in the desired amounts of about 100 mg and 1 mg, respectively. The product may also contain riboflavin in an amount between about 1 mg and about 3 mg, pyridoxine in an amount between about 1 mg and about 3 mg, cyanocobalamin in an amount between about 6 mg and about 12 mg, biotin in an amount between about 10 mcg and about 50 mcg, niacin in an amount between about 10 mg and about 50 mg, vitamin D in an amount between about 200 IU and about 500 IU, vitamin E in an amount between about 10 IU and about 50 IU, selenium in an amount between about 5 mcg and about 50 mcg, and/or magnesium in an amount between about 100 mg and about 400 mg.Type: GrantFiled: June 25, 1999Date of Patent: June 12, 2001Inventor: John S. Markowitz
-
Patent number: 6245740Abstract: The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent. The described protein/glycerol/oil suspensions show sustained release of protein, e.g., G-CSF, of up to at least one week.Type: GrantFiled: December 23, 1998Date of Patent: June 12, 2001Assignee: Amgen Inc.Inventors: Merrill Goldenberg, Daxian Shan, Alice Beekman
-
Patent number: 6245354Abstract: The present invention relates to a pharmaceutical sustained release preparation prepared by using as a sustained release ingredient a partial degradation product of the galactose of a galactoxyloglucan and a method for sustained releasing of a drug thereby. In more detail, it relates to a pharmaceutical sustained release preparation, wherein the sustained release of a drug is effected by utilizing the thermally reversible gel characteristics of the galactose-partial degradation product, which is produced by partial removal of the galactose on the side-chain of a galactoxyloglucan with an enzyme.Type: GrantFiled: August 12, 1998Date of Patent: June 12, 2001Assignee: Dainippon Pharmaceutical Co., Ltd.Inventors: Shozo Miyazaki, Mayumi Shirakawa, Kazuhiko Yamatoya
-
Patent number: 6235726Abstract: A water insoluble, biocompatible composition that includes the reaction product of a polyanionic polysaccharide and an activating agent.Type: GrantFiled: August 18, 1999Date of Patent: May 22, 2001Assignee: Genzyme CorporationInventors: James W. Burns, Robert Miller
-
Patent number: 6228894Abstract: A softgel-compatible composition containing retinol comprises retinol-impregnated microparticles. The composition may include an optionally thickened silicone oil, or may include an emulsion comprising a silicone oil. Ascorbic acid may be present as ascorbic acid-impregnated microparticles and/or within the emulsion. Such compositions are compatible with softgels, and may also be used in other dispensing containers, such as sachets, tubes, and airless pumps.Type: GrantFiled: March 19, 1999Date of Patent: May 8, 2001Assignees: Enhanced Derm Technologies, Inc., R. P. Scherer CorporationInventors: Marie A. Rinaldi, Subhash J. Saxena, Paul C. Tutschek
-
Patent number: 6221853Abstract: The invention relates to a lactulose-based medicinal product, characterized by the incorporation of anhydrous lactulose into a coating vehicle, which is also anhydrous, consisting of a mixture of pharmaceutically acceptable purified paraffinic hydrocarbons, this vehicle having a melting point of about 37° C.±4° C. It is, in particular, dosed so as to allow the administration of 3 to 5 g per day to an adult, in particular in a single dosage intake.Type: GrantFiled: October 21, 1998Date of Patent: April 24, 2001Inventors: Odette M. Salsarulo, Gerard Salsarulo
-
Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
Patent number: 6207178Abstract: The present invention is in the area of administration forms and delivery systems for drugs, vaccines and other biologically active agents. More specifically the invention is related to the preparation of suspensions of colloidal solid lipid particles (SLPs) of predominantly anisometrical shape with the lipid matrix being in a stable polymorphic modification and of suspensions of micron and submicron particles of bioactive agents (PBAs); as well as to the use of such suspensions or the lyophilizates thereof as delivery systems primarily for the parenteral administration of preferably poorly water-soluble bioactive substances, particularly drugs, and to their use in cosmetic, food and agricultural products. SLPs and PBAs are prepared by the following emulsification process: (1) A solid lipid or bioactive agent or a mixture of solid lipids or bioactive agents is melted.Type: GrantFiled: December 3, 1998Date of Patent: March 27, 2001Assignee: Kabi Pharmacia ABInventors: Kirsten Westesen, Britta Siekmann -
Patent number: 6204255Abstract: Non-deliquescent formulation comprising or consisting of sodium valproate and cyclodextrin having a molar ratio of sodium valproate to cyclodextrin within the range of from 1:0.01 to 1:0.09.Type: GrantFiled: May 24, 1999Date of Patent: March 20, 2001Assignee: Hexal AGInventor: Karin Klokkers
-
Patent number: 6197344Abstract: Controlled, sustained release formulations of butorphanol are provided. Such formulations can be an aqueous suspension of butorphanol freebase or an oil suspension of a butorphanol salt. Processes for using such formulations to provide long term analgesia are also provided.Type: GrantFiled: October 28, 1999Date of Patent: March 6, 2001Assignee: Abbott LaboratoriesInventors: Hung-Chih Chang, Lukchiu Li, Youqin Tian
-
Patent number: 6197781Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.Type: GrantFiled: August 13, 1999Date of Patent: March 6, 2001Assignee: Novartis AGInventors: Patrice Guitard, Barbara Haeberlin, Rainer Link, Friedrich Richter
-
Patent number: 6190702Abstract: A sustained-release preparation containing a bioactive polypeptide is prepared using a starting material containing a lyophilized product of an aqueous solution or suspension of the bioactive polypeptide in a non-ionic surfactant. The lyophilized product is dispersed in an oil phase, which further contains a biocompatible, biodegradable polymer.Type: GrantFiled: May 30, 1997Date of Patent: February 20, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Shigeyuki Takada, Tomofumi Kurokawa, Susumu Iwasa
-
Patent number: 6190700Abstract: Disclosed is a method of producing a sustained-release preparation for injection, which comprises adding to microspheres which are obtained from w/o emulsion with a solution containing a physiologically active peptide as an internal aqueous phase and a solution containing a polylactic acid having a weight-average molecular weight of about 5,000 to about 25,000 as an oil phase, a sugar in an amount of about 2 to about 60% (w/w) relative to the microspheres; freeze drying and subsequent heating at the temperature ranging from the glass transition temperature of the microspheres to the temperature which is higher by about 20° C. than the glass transition temperature for about 24 to about 120 hours; and the method of the present invention suppresses microsphere particle aggregation during production process, makes it possible to almost perfectly remove the water and organic solvent in microspheres, and yields microspheres having good dispersibility and storage-stability.Type: GrantFiled: December 13, 1996Date of Patent: February 20, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Hiroaki Okada, Yayoi Douken, Akihiro Yamada
-
Patent number: 6190680Abstract: An oily composition comprises a solid phase containing a water-soluble effective substance and/or a water-dispersible effective substance and an oil phase containing an oily component and an emulsifying agent having an HLB value of not more than 10, wherein the solid phase is dispersed in the oil phase in the form of a fine particulate state having an average particle size of not more than 5 &mgr;m and the water content or the aqueous alcohol solution content of the solid phase is not more than 30% by weight.Type: GrantFiled: March 31, 1999Date of Patent: February 20, 2001Assignee: The Nisshin Oil Mills, Ltd.Inventors: Satoshi Sakurada, Hisako Yoshino
-
Patent number: 6174873Abstract: Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compositions including adenosine analogs, wherein the composition is in a dosage form comprising a liquid. Additionally disclosed are methods of administering the inventive composition, and kits including the inventive compositions.Type: GrantFiled: November 4, 1998Date of Patent: January 16, 2001Assignee: SuperGen, Inc.Inventor: Simeon M. Wrenn, Jr.
-
Patent number: 6165503Abstract: In the formation of capsules having a polyanionic polysaccharide core and a polycationic polysaccharide membrane layer, improved binding of the polycationic polysaccharide is achieved by including polyvalent ions, especially calcium ions, at the membrane forming step.Type: GrantFiled: July 1, 1998Date of Patent: December 26, 2000Assignee: FMC Biopolymer A.S.Inventors: Olav G.ang.ser.o slashed.d, .O slashed.ivind Skaugrud, Peter Dettmar, Gudmund Sj.ang.k-Braek, Ian Jolliffe